welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne Scholarship Program. This is the second year of the scholarship program which was created to recognize exceptional individuals with Duchenne muscular dystrophy as they pursue their post-secondary education. Twenty-three recipients were chosen by an independent selection committee comprised of Duchenne community members based on each applicant’s community involvement and a personal essay. Each of the students will receive scholarships of up to $5,000.
rareRelated
-
Duchenne Muscular Dystrophy Tissue Bank for Exon SkippingWe will utilize the Cooperative Internat...
-
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on CorticosteroidsThe purpose of the study is to assess th...
-
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
-
Catabasis Quarterly: Updates on edasalonexent and clinical trialsHappy New Year! As 2019 kicks off, our P...
-
Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)The purpose of this study is to see whet...
-
Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 SkippingThis is a multicenter, open-label, dose-...
-
cTAP Study Shows Real-World, Natural History Data Comparable To Placebo Data From Clinical Trials In Duchenne Muscul...CAMBRIDGE, Mass., Sept. 8, 2020 /PRNew...
-
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular D...SAN FRANCISCO, Aug. 11, 2020 (GLOBE NE...
-
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patie...Sarepta Therapeutics, Inc., a leader in ...
-
Solid Biosciences Provides SGT-001 Program UpdateCAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE...
